ARF1 and neoplasm: Together, our data suggested that the treatment with the new Arf1 inhibitors did not directly kill tumor cells rather than enhanced anti‐tumor immunity through promoting T cell tumor infiltration, T cell activation through releasing ATP and T cell differentiation toward a durable memory T cell population, consistent with our previously reported effects of genetic ablation of Arf1.